A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for KDventures AB's Debt-to-EBITDA or its related term are showing as below:
KDEVF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.3 Med: 0.13 Max: 5.98
Current: -0.05
During the past 13 years, the highest Debt-to-EBITDA Ratio of KDventures AB was 5.98. The lowest was -2.30. And the median was 0.13.
KDEVF's Debt-to-EBITDA is ranked worse than 100% of 292
companies
in the Biotechnology industry
Industry Median: 1.215
vs KDEVF: -0.05
KDventures AB (OTCPK:KDEVF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
KDventures AB Debt-to-EBITDA Related Terms
KDventures AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for KDventures AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KDEVF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, KDventures AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KDventures AB Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, KDventures AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where KDventures AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
KDventures AB (KDEVF) has a Debt-to-EBITDA of -0.04 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on KDventures AB. According to the industry distribution chart, KDventures AB ranks #999999 out of 292 companies in the Biotechnology industry.
Is KDventures AB's Debt-to-EBITDA too high?
KDventures AB's current Debt-to-EBITDA is -0.04. Based on the distribution chart, KDventures AB ranks #999999 out of 292 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, KDventures AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does KDventures AB's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, KDventures AB ranks #999999 out of 292 companies for Debt-to-EBITDA. This places KDventures AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 292 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on KDventures AB. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KDventures AB's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KDventures AB stock overvalued right now?
KDventures AB (KDEVF) has a current Debt-to-EBITDA of -0.04. The stock's GF Value™ is $0.67, compared to a current price of $0.26 — trading 61.6% below its estimated fair value. The current Debt-to-EBITDA is -0.04. KDventures AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For KDventures AB (KDEVF), the current Debt-to-EBITDA is -0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KDventures AB (KDEVF) Overvalued in 2026?
Based on GuruFocus' analysis, KDventures AB stock appears to be undervalued.
The current stock price of $0.26 is trading 61.6% below its estimated GF Value™ of $0.67.
Key valuation signals for KDEVF:
Debt-to-EBITDA: -0.04
GF Value™: $0.67 vs. price of $0.26 (61.6% below fair value)
No single metric tells the full story. See the KDEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KDventures AB is a Nordic investment company specialized in life sciences. The company identifies and invests in pharmaceutical projects and medical technology products originating from research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, the company creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with value growth potential.
30GF Score
Get the complete analysis for KDEVF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KDEVF has been successfully added to your 
